Chondroitin Sulfate and Hyaluronic Acid Perfusion for Interstitial Cystitis/Bladder Pain Syndrome
A Systematic Review and Meta-Analysis

Xiang Xiao,¹,⁶ Huan Deng,¹,⁴ Mumba Mulutula Chilufya,¹ Yizhen Lv,¹
Yan Zhao,¹ Jiaxin Liu,¹ Ziwei Guo,¹ Lichun Qiao,¹ Jing Han,¹,*
Dong Wang,²,* Chengjuan Qu³

1. School of Public Health, Xi’an Jiaotong University, Xi’an 710061, Shaanxi, P. R. China
2. Key Laboratory of Biomedical Engineering of Hainan Province, School of Biomedical Engineering, Hainan University, Haikou 570228, Hainan, P. R. China
3. Department of Odontology, Umeå University, Umeå, 90185, Sweden
*¹ These authors contributed equally to this work.
*² All corresponding should be sent to Drs. Jing Han and Dong Wang.

Authors’ Contact: Xiang Xiao, E-mail: m18064304317@163.com, ORCID: 0000-0003-4053-1706; Huan Deng, E-mail: 957336248@qq.com, ORCID: 0000-0002-4298-3581; Mumba Mulutula Chilufya, E-mail: mumba.mmc@gmail.com, ORCID: 0000-0001-7812.022X; Yizhen Lv, E-mail: yizhenlv81@163.com, ORCID: 0000-0002-8376-0747; Yan Zhao, E-mail: 2533218374@qq.com, ORCID: 0000-0002-7116-8631; Jiaxin Liu, E-mail: lx11780929471@163.com, ORCID: 0000-0001-9335-6679; Zwei Guo, E-mail: 1048116303@qq.com, ORCID: 0000-0002-8371-840X; Lichun Qiao, E-mail: 978402409@qq.com, ORCID: 0000-0002-6739-0846; Jing Han, E-mail: bbbishop@126.com, ORCID: 0000-0003-1460-0114; Dong Wang, E-mail: wangdong@hainanu.edu.cn, ORCID: 0000-0002-8209-210X; Chengjuan Qu, E-mail: chengjuan.qu@umu.se, ORCID: 0000-0002-1710-7715.

Funding: This work was funded by the National Natural Science Foundation of China (#81872567).

DOI: https://doi.org/10.15354/si.21.ep001

The authors declare no competing interest.

It has been brought to authors attention that there is a missing part in “Materials and Methods” of the Systematic Review article by Xiao et al., entitled “Chondroitin Sulfate and Hyaluronic Acid Perfusion for Interstitial Cystitis/Bladder Pain Syndrome: A Systematic Review and Meta-Analysis” in the Volume 39, No. 4 of Science Insights (pp.363-373).

The missing part of the “Materials and Methods” is as below:

**Population: Patients with IC/BPS.**

**Intervention:** All patients underwent intravesical HA and/or CS treatment regimen.

**Comparison:** Improvement in symptoms pre-treatment and post-treatment or other treatment regimen.

**Outcome:** The primary outcome was the change in visual analogue scale (VAS) for pain symptom from baseline to the follow-up period; secondary outcomes were the changes in total scores of the O’Leary-Sant Interstitial Cystitis Symptom Index (ICSI) and Problem Index (ICPI), storage symptoms including frequency and urgency, and bladder capacity.

Science Insights, 2021 December 28; Vol. 39, No. 5, pp.419.